Innovation in Cardiology--and Beyond.

For years, cardiovascular devices were the main focus of venture investors and the start-ups they backed. But in recent years, innovation in cardiovascular has grown more challenging, perhaps in part because of the way drug-eluting stents have reshaped the market, while other clinical spaces have opened up as promising technological and commercials opportunities. In this discussion, a distinguished group of physicians, product developers, and entrepreneurs look at where innovation is going and the challenges small companies face.

Few would contest that the past quarter-century has seen an explosion of medical device technology that has brought incalculable benefit to patients and, despite some down times, abundant riches to inventors and the investors who’ve backed them. By its very nature, device innovation is incremental: most often serving as tools in the hands of skilled physicians and surgeons, innovative devices build on the clinical success of existing technology in enhancements large and small, though usually small. It is an innovation model that has served the device industry well.

And yet, despite the clinical advances and financial successes that have flowed from new technology, fostering meaningful innovation seems only...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.